NY-SK-CAPITAL-PARTNERS
16.2.2021 08:02:11 CET | Business Wire | Press release
SK Capital Partners, LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, today announced it will be expanding its team with the addition of Daniele Ferrari as Senior Director.
Mr. Ferrari brings over 35 years of direct operating and executive experience in the chemicals industry, most recently serving as the CEO of Versalis S.p.A., one of Europe’s largest chemicals companies, and as Chairman of Matrìca S.p.A., a joint-venture with Novamont, a leader in the bio-plastics industry at the forefront of the renewable chemistry sector. At Versalis S.p.A., Mr. Ferrari led the company’s efforts to reposition downstream and grow the company’s portfolio of higher margin, specialty and renewable chemical products, including creating the company’s BioTech global business unit. Mr. Ferrari started his career at Agip Petroli, a subsidiary of Eni S.p.A., and Imperial Chemical Industries (ICI), before joining Huntsman in 1997, where he held numerous roles and international assignments spanning his 14 year tenure, during which he ultimately became the global President of Huntsman’s Performance Products division.
Mr. Ferrari also brings significant leadership in the area of sustainability, promoting processes that support a more circular economy and the development and usage of renewable chemical solutions. He was the immediate past President of the European Chemical Industry Council (CEFIC), which is the largest trade association for the chemical industry in Europe. He previously served as President of PlasticsEurope Bruxelles, the association of European plastics manufacturers, and as a board member of Alliance to End Plastics Waste.
Mr. Ferrari has an Industrial Chemical background and was awarded an Honorary Master’s degree in Chemical Sciences from the University of Ferrara. He currently serves as a director on the boards of Huntsman Corporation (NYSE: HUN) and Venator Materials PLC (NYSE: VNTR), where he chairs the Audit Committee. Mr. Ferrari also serves on the board of the Oxford University Business Economics Program.
Barry Siadat, Co-Founder and Managing Director at SK Capital, commented, "Daniele brings an unparalleled level of operating and executive leadership experience to the firm. He has successfully led multiple companies within the chemical industry for decades and shares a strong passion for sustainability." Siadat added, "Daniele’s deep knowledge of and experience in our sectors of focus make him an ideal match for his new position at SK Capital."
"SK Capital is well-known in the industry for leveraging its operating and investing expertise to drive business transformation and improvement," said Mr. Ferrari. "I am delighted to join the SK Capital team and look forward to supporting the firm's ongoing growth and success."
Jamshid Keynejad, Co-Founder and Managing Director at SK Capital, commented, “Daniele is a proven leader in our industry who brings a unique skillset and decades of operating experience to SK Capital. We are excited to add him to our team and we look forward to working together to enhance the value of our portfolio and support the growth of our firm.”
ABOUT SK CAPITAL
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $11 billion annually, employs more than 15,000 people globally and operates 137 plants in 28 countries. The firm currently has approximately $4.86 billion of assets under management. For more information, please visit www.skcapitalpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005389/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 19:06:00 CET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
